HBM Holdings to Launch Clinical Trials for COPD Drug in China

An update from HBM Holdings Ltd. ( (HK:2142) ) is now available.

HBM Holdings Limited has announced that it has received clearance from China’s National Medical Products Administration to initiate clinical trials for its investigational new drug, HBM9378/SKB378, aimed at treating chronic obstructive pulmonary disease (COPD). This development comes as part of a global licensing agreement with Windward Bio AG, potentially bringing significant financial benefits to HBM Holdings through upfront, milestone, and royalty payments. This clearance marks a significant step in enhancing the company’s positioning in the biopharmaceutical industry, especially in the respiratory treatment segment, and highlights its strategic collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

More about HBM Holdings Ltd.

HBM Holdings Limited is a company incorporated in the Cayman Islands, focusing on the biotechnology and pharmaceutical industry. It co-develops innovative therapies, such as monoclonal antibodies, for the treatment of various diseases. One of its primary products, HBM9378/SKB378, is developed in collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with a market focus in Greater China and several Southeast and West Asian countries.

YTD Price Performance: 101.08%

Average Trading Volume: 4,151,906

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$2.82B

See more data about 2142 stock on TipRanks’ Stock Analysis page.